Cargando…
Benefit of COVID-19 vaccination accounting for potential risk compensation
People receiving COVID-19 vaccines may subsequently markedly increase their previously suppressed exposure risk. A simple model can evaluate the benefit of vaccination to the vaccinated (index) person and others exposed to that person; and calculate the amount of risk compensation required to elimin...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358049/ https://www.ncbi.nlm.nih.gov/pubmed/34381059 http://dx.doi.org/10.1038/s41541-021-00362-z |
_version_ | 1783737254542311424 |
---|---|
author | Ioannidis, John P. A. |
author_facet | Ioannidis, John P. A. |
author_sort | Ioannidis, John P. A. |
collection | PubMed |
description | People receiving COVID-19 vaccines may subsequently markedly increase their previously suppressed exposure risk. A simple model can evaluate the benefit of vaccination to the vaccinated (index) person and others exposed to that person; and calculate the amount of risk compensation required to eliminate all the benefits or to halve the benefit. As shown, 2.5-fold increase in exposure will eliminate the benefit of a vaccine of moderate efficacy (E = 0.6) unless the probability of infection in the population of interest is very high. With very high vaccine efficacy (E = 0.95), substantial benefit is maintained except in situations where there is a very low probability of infection in the population. If the vaccine efficacy decreases to 0.8, the benefit gets eroded easily with modest risk compensation. Risk compensation may markedly affect the benefit of COVID-19 vaccination, especially if vaccine efficacy in real-life or specific high-risk populations (e.g., nursing home residents) is not very high. |
format | Online Article Text |
id | pubmed-8358049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-83580492021-08-30 Benefit of COVID-19 vaccination accounting for potential risk compensation Ioannidis, John P. A. NPJ Vaccines Article People receiving COVID-19 vaccines may subsequently markedly increase their previously suppressed exposure risk. A simple model can evaluate the benefit of vaccination to the vaccinated (index) person and others exposed to that person; and calculate the amount of risk compensation required to eliminate all the benefits or to halve the benefit. As shown, 2.5-fold increase in exposure will eliminate the benefit of a vaccine of moderate efficacy (E = 0.6) unless the probability of infection in the population of interest is very high. With very high vaccine efficacy (E = 0.95), substantial benefit is maintained except in situations where there is a very low probability of infection in the population. If the vaccine efficacy decreases to 0.8, the benefit gets eroded easily with modest risk compensation. Risk compensation may markedly affect the benefit of COVID-19 vaccination, especially if vaccine efficacy in real-life or specific high-risk populations (e.g., nursing home residents) is not very high. Nature Publishing Group UK 2021-08-11 /pmc/articles/PMC8358049/ /pubmed/34381059 http://dx.doi.org/10.1038/s41541-021-00362-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Ioannidis, John P. A. Benefit of COVID-19 vaccination accounting for potential risk compensation |
title | Benefit of COVID-19 vaccination accounting for potential risk compensation |
title_full | Benefit of COVID-19 vaccination accounting for potential risk compensation |
title_fullStr | Benefit of COVID-19 vaccination accounting for potential risk compensation |
title_full_unstemmed | Benefit of COVID-19 vaccination accounting for potential risk compensation |
title_short | Benefit of COVID-19 vaccination accounting for potential risk compensation |
title_sort | benefit of covid-19 vaccination accounting for potential risk compensation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358049/ https://www.ncbi.nlm.nih.gov/pubmed/34381059 http://dx.doi.org/10.1038/s41541-021-00362-z |
work_keys_str_mv | AT ioannidisjohnpa benefitofcovid19vaccinationaccountingforpotentialriskcompensation |